Drug delivery with living cells

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 63-72

  Fliervoet, Lies A L ^a   Mastrobattista, Enrico ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Biopharmaceutics; Cell engineering; Cell therapy; Nanomedicine; Synthetic biology

Indexed keywords

CELLS; CYTOLOGY; GENE THERAPY; GENETIC ENGINEERING; MEDICAL NANOTECHNOLOGY; MOLECULES; NEXT GENERATION NETWORKS;

BIOACTIVE PROTEINS; BIOPHARMACEUTICS; CELL THERAPY; CELL-BASED DRUG DELIVERIES; DRUG DELIVERY SYSTEM; NEXT GENERATION SYSTEMS; SYNTHETIC BIOLOGY; THERAPEUTIC MOLECULES;

CELL ENGINEERING;

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DRUG BINDING PROTEIN; PRODRUG; DRUG;

BIOCHEMISTRY; CANCER CELL; CELL ENCAPSULATION; CELL ENGINEERING; CELL SURFACE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ELECTROENCEPHALOGRAM; ENCAPSULATION; ERYTHROCYTE; GAMMA IRRADIATION; GENETIC ENGINEERING; GLUCOSE HOMEOSTASIS; HUMAN; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; STEM CELL; SYNTHETIC BIOLOGY; T LYMPHOCYTE; TUMOR CELL; ANIMAL; CELL SURVIVAL; CELLS; PROCEDURES; SECRETION (PROCESS);

ANIMALS; CELL SURVIVAL; CELLS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; SYNTHETIC BIOLOGY;

EID: 84973866805     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.021     Document Type: Review

References (131)

1. [1] Fang, J., Nakamura, H., Maeda, H., The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63 (2011), 136–151.
2. [2] Varkouhi, A.K., Scholte, M., Storm, G., Haisma, H.J., Endosomal escape pathways for delivery of biologicals. J. Control. Release 151 (2011), 220–228.
3. [3] Singha, K., Namgung, R., Kim, W.J., Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 21 (2011), 133–147.
4. [4] Magnani, M., Rossi, L., Approaches to erythrocyte-mediated drug delivery. Expert Opin. Drug Deliv. 11 (2014), 1–11.
5. [5] Lee, C.-H., Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. Appl. Microbiol. Biotechnol. 93 (2012), 517–523.
6. [6] Burke, B., Sumner, S., Maitland, N., Lewis, C.E., Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J. Leukoc. Biol. 72 (2002), 417–428.
7. [7] Kemmer, C.et al., Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat. Biotechnol. 28 (2010), 355–360.
8. [8] Kemmer, C.et al., A designer network coordinating bovine artificial insemination by ovulation-triggered release of implanted sperms. J. Control. Release 150 (2011), 23–29.
9. [9] Ihler, G.M., Glew, R.H., Schnure, F.W., Enzyme loading of erythrocytes. Proc. Natl. Acad. Sci. U. S. A. 70 (1973), 2663–2666.
10. [10] Biagiotti, S., Paoletti, M.F., Fraternale, A., Rossi, L., Magnani, M., Drug delivery by red blood cells. IUBMB Life 63 (2011), 621–631.
11. [11] Pierigè, F., Serafini, S., Rossi, L., Magnani, M., Cell-based drug delivery. Adv. Drug Deliv. Rev. 60 (2008), 286–295.
12. [12] Biagiotti, S.et al., Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. J. Control. Release 154 (2011), 306–313.
13. [13] Rossi, L.et al., Erythrocyte-based drug delivery. Expert Opin. Drug Deliv. 2 (2005), 311–322.
14. [14] Leuzzi, V.et al., Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol. Neuroimmunol. Neuroinflammation, 2, 2015, e98.
15. [15] Muzykantov, V.R., Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin. Drug Deliv. 7 (2010), 403–427.
16. [16] Muro, S., Schuchman, E.H., Muzykantov, V.R., Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol. Ther. 13 (2006), 135–141.
17. [17] Bax, B.E.et al., A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency. Eur. J. Haematol. 79 (2007), 338–348.
18. [18] Bachet, J.-B.et al., Asparagine synthetase expression and phase i study with l-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma. Pancreas 44 (2015), 1141–1147.
19. [19] Hamidi, M., Azimi, K., Mohammadi-Samani, S., Co-encapsulation of a drug with a protein in erythrocytes for improved drug loading and release: phenytoin and bovine serum albumin (BSA). J. Pharm. Pharm. Sci. 14 (2011), 46–59.
20. [20] Danielyan, K.et al., Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation 118 (2008), 1442–1449.
21. [21] Murray, A.M.et al., The mouse immune response to carrier erythrocyte entrapped antigens. Vaccine 24 (2006), 6129–6139.
22. [22] Taylor, R.P.et al., In vivo binding and clearance of circulating antigen by bispecific heteropolymer-mediated binding to primate erythrocyte complement receptor. J. Immunol. 148 (1992), 2462–2468.
23. [23] Chambers, E., Mitragotri, S., Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp. Biol. Med. (Maywood), 232(958–966), 2007.
24. [24] Anselmo, A.C.et al., Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 7 (2013), 11129–11137.
25. [25] Gorantla, S.et al., Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J. Leukoc. Biol. 80 (2006), 1165–1174.
26. [26] Dou, H.et al., Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183 (2009), 661–669.
27. [27] Dou, H.et al., Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358 (2007), 148–158.
28. [28] Dou, H.et al., Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108 (2006), 2827–2835.
29. [29] Nowacek, A.S.et al., Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. NeuroImmune Pharmacol. 5 (2010), 592–601.
30. [30] Batrakova, E.V., Gendelman, H.E., Kabanov, A.V., Cell-mediated drug delivery. Expert Opin. Drug Deliv. 8 (2011), 415–433.
31. [31] Nowacek, A.S.et al., Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J. Control. Release 150 (2011), 204–211.
32. [32] Choi, M.et al., A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7 (2007), 3759–3765.
33. [33] Champion, J.A., Katare, Y.K., Mitragotri, S., Making polymeric micro- and nanoparticles of complex shapes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 11901–11904.
34. [34] Gilboa, E., Nair, S.K., Lyerly, H.K., Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46 (1998), 82–87.
35. [35] Nencioni, A.et al., The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 65 (2008), 191–199.
36. [36] Banchereau, J., Palucka, A.K., Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5 (2005), 296–306.
37. [37] Kantoff, P.W.et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (2010), 411–422.
38. [38] Wang, D.et al., Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 14, 2014, 251.
39. [39] Davis, I.D., Jefford, M., Parente, P., Cebon, J., Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73 (2003), 3–29.
40. [40] Dove, A., Cell-based therapies go live. Nat. Biotechnol. 20 (2002), 339–343.
41. [41] Jena, B., Moyes, J.S., Huls, H., Cooper, L.J.N., Driving CAR-based T-cell therapy to success. Curr. Hematol. Malig. Rep. 9 (2014), 50–56.
42. [42] Forbes, N.S., Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10 (2010), 785–794.
43. [43] Wei, M.Q.et al., Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur. J. Cancer 43 (2007), 490–496.
44. [44] Nguyen, V.H.et al., Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res. 70 (2010), 18–23.
45. [45] Loeffler, M., Le'Negrate, G., Krajewska, M., Reed, J.C., Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol. Immunother. 58 (2009), 769–775.
46. [46] Nishikawa, H.et al., In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 116 (2006), 1946–1954.
47. [47] Massa, P.E., Paniccia, A., Monegal, A., de Marco, A., Rescigno, M., Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood 122 (2013), 705–714.
48. [48] Cheng, C.-M.et al., Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Ther. 15 (2008), 393–401.
49. [49] Minton, N.P., Clostridia in cancer therapy. Nat. Rev. Microbiol. 1 (2003), 237–242.
50. [50] Malmgren, R.A., Flanigan, C.C., Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 15 (1955), 473–478.
51. [51] Lemmon, M.J.et al., Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4 (1997), 791–796.
52. [52] Morrissey, D., O'Sullivan, G.C., Tangney, M., Tumour targeting with systemically administered bacteria. Curr. Gene Ther. 10 (2010), 3–14.
53. [53] Kasinskas, R.W., Forbes, N.S., Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol. Bioeng. 94 (2006), 710–721.
54. [54] Brown, J.M., Wilson, W.R., Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 (2004), 437–447.
55. [55] Roberts, N.J.et al., Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci. Transl. Med. 6 (2014), 1–11.
56. [56] Theys, J., Lambin, P., Clostridium to treat cancer: dream or reality?. Ann. Transl. Med., 3, 2015, S21.
57. [57] Ankrum, J., Karp, J.M., Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol. Med. 16 (2010), 203–209.
58. [58] Aboody, K.et al., Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. U. S. A. 97 (2001), 12846–12851.
59. [59] Park, K.I.et al., Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic–ischemic brain injury. Exp. Neurol. 199 (2006), 179–190.
60. [60] Alieva, M.et al., Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response. PLoS One 7 (2012), 1–11.
61. [61] Bagó, J.R., Sheets, K.T., Hingtgen, S.D., Neural stem cell therapy for cancer. Methods. 99 (2016), 37–43.
62. [62] Song, K., Benhaga, N., Anderson, R.L., Khosravi-Far, R., Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res. 66 (2006), 6304–6311.
63. [63] Corsten, M.F., Shah, K., Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol. 9 (2008), 376–384.
64. [64] Elzaouk, L., Moelling, K., Pavlovic, J., Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp. Dermatol. 15 (2006), 865–874.
65. [65] Levy, O.et al., mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 122 (2013), e23–e32.
66. [66] Shah, K., Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Deliv. Rev. 64 (2012), 739–748.
67. [67] Cavarretta, I.T.et al., Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol. Ther. 18 (2010), 223–231.
68. [68] Aboody, K.S.et al., Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-Oncology 8 (2006), 119–126.
69. [69] van Eekelen, M.et al., Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 29 (2010), 3185–3195.
70. [70] Freeman, S.M.et al., The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53 (1993), 5274–5283.
71. [71] Dranoff, G.et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 3539–3543.
72. [72] Hege, K.M., Jooss, K., Pardoll, D., GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int. Rev. Immunol. 25 (2006), 321–352.
73. [73] Nelson, W.G.et al., Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol.(46 Suppl), 2000, S67–S72.
74. [74] Lutz, E.et al., A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253 (2011), 328–335.
75. [75] Simons, J.W.et al., Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 (1999), 5160–5168.
76. [76] Wieczorek, A., Uharek, L., Genetically modified T cells for the treatment of malignant disease. Transfus. Med. Hemother. 40 (2013), 388–402.
77. [77] Weber, J.S., At the bedside: adoptive cell therapy for melanoma—clinical development. J. Leukoc. Biol. 95 (2014), 1–8.
78. [78] Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
79. [79] Berger, C.et al., Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114 (2009), 2417–2426.
80. [80] Stephan, M.T., Moon, J.J., Um, S.H., Bershteyn, A., Irvine, D.J., Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16 (2010), 1031–1037.
81. [81] Zheng, Y.et al., In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J. Control. Release 172 (2013), 426–435.
82. [82] Stephan, M.T., Irvine, D.J., Enhancing cell therapies from the outside in: cell surface engineering using synthetic nanomaterials. Nano Today 6 (2011), 309–325.
83. [83] Folcher, M., Fussenegger, M., Synthetic biology advancing clinical applications. Curr. Opin. Chem. Biol. 16 (2012), 345–354.
84. [84] Weber, W., Fussenegger, M., Emerging biomedical applications of synthetic biology. Nat. Rev. Genet. 13 (2012), 21–35.
85. [85] McDaniel, R., Weiss, R., Advances in synthetic biology: on the path from prototypes to applications. Curr. Opin. Biotechnol. 16 (2005), 476–483.
86. [86] Gübeli, R.J., Burger, K., Weber, W., Synthetic biology for mammalian cell technology and materials sciences. Biotechnol. Adv. 31 (2013), 68–78.
87. [87] Weber, W., Fussenegger, M., Pharmacologic transgene control systems for gene therapy. J. Gene Med. 8 (2006), 535–556.
88. [88] Indraccolo, S.et al., Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors. Gene Ther. 13 (2006), 953–965.
89. [89] Gitzinger, M., Kemmer, C., El-Baba, M.D., Weber, W., Fussenegger, M., Controlling transgene expression in subcutaneous implants using a skin lotion containing the apple metabolite phloretin. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 10638–10643.
90. [90] Gitzinger, M.et al., The food additive vanillic acid controls transgene expression in mammalian cells and mice. Nucleic Acids Res., 40, 2012, e37.
91. [91] Palli, S.R., Kapitskaya, M.Z., Potter, D.W., The influence of heterodimer partner ultraspiracle/retinoid X receptor on the function of ecdysone receptor. FEBS J. 272 (2005), 5979–5990.
92. [92] Fussenegger, M.et al., Streptogramin-based gene regulation systems for mammalian cells. Nat. Biotechnol. 18 (2000), 1203–1208.
93. [93] Hartenbach, S., Daoud-El Baba, M., Weber, W., Fussenegger, M., An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice. Nucleic Acids Res., 35, 2007, e136.
94. [94] Weber, W., Bacchus, W., Daoud-El Baba, M., Fussenegger, M., Vitamin H-regulated transgene expression in mammalian cells. Nucleic Acids Res., 35, 2007, e116.
95. [95] Anderson, J.C., Clarke, E.J., Arkin, A.P., Voigt, C.A., Environmentally controlled invasion of cancer cells by engineered bacteria. J. Mol. Biol. 355 (2006), 619–627.
96. [96] Dersch, P., Isberg, R.R., A region of the Yersinia pseudotuberculosis invasin protein enhances integrin-mediated uptake into mammalian cells and promotes self-association. EMBO J. 18 (1999), 1199–1213.
97. [97] Schleif, R., AraC protein: a love–hate relationship. BioEssays News Rev. Mol. Cell. Dev. Biol. 25 (2003), 274–282.
98. [98] Salmon, K.et al., Global gene expression profiling in Escherichia coli K12. The effects of oxygen availability and FNR. J. Biol. Chem. 278 (2003), 29837–29855.
99. [99] Surette, M.G., Bassler, B.L., Quorum sensing in Escherichia coli and Salmonella typhimurium. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 7046–7050.
100. [100] Bacchus, W., Fussenegger, M., The use of light for engineered control and reprogramming of cellular functions. Curr. Opin. Biotechnol. 23 (2012), 695–702.
101. [101] Kim, T., Folcher, M., El Baba, M.D., Fussenegger, M., A synthetic erectile optogenetic stimulator enabling blue-light-inducible penile erection. Angew. Chem. Int. Ed. 54 (2015), 5933–5938.
102. [102] Weber, W.et al., Gas-inducible transgene expression in mammalian cells and mice. Nat. Biotechnol. 22 (2004), 1440–1444.
103. [103] Ganai, S., Arenas, R.B., Forbes, N.S., Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br. J. Cancer 101 (2009), 1683–1691.
104. [104] Terán, W., Krell, T., Ramos, J.L., Gallegos, M.-T., Effector-repressor interactions, binding of a single effector molecule to the operator-bound TtgR homodimer mediates derepression. J. Biol. Chem. 281 (2006), 7102–7109.
105. [105] Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S., Roth, B.L., Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 5163–5168.
106. [106] Urban, D.J., Roth, B.L., DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): chemogenetic tools with therapeutic utility. Annu. Rev. Pharmacol. Toxicol. 55 (2015), 399–417.
107. [107] Ye, H.et al., Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 141–146.
108. [108] Nissim, L., Bar-Ziv, R.H., A tunable dual-promoter integrator for targeting of cancer cells. Mol. Syst. Biol., 6, 2010, 444.
109. [109] Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
110. [110] Ye, H., Daoud-El Baba, M., Peng, R.-W., Fussenegger, M., A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 332 (2011), 1565–1568.
111. [111] Rubí, B., Maechler, P., Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance. Endocrinology 151 (2010), 5570–5581.
112. [112] Rössger, K., Hamri, G.C., Fussenegger, M., Reward-based hypertension control by a synthetic brain-dopamine interface. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 18150–18155.
113. [113] Folcher, M.et al., Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant. Nat. Commun. 5 (2014), 1–11.
114. [114] Grundy, S.M., Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 5 (2006), 295–309.
115. [115] Liebman, S.E., Taylor, J.G., Bushinsky, D.A., Uric acid nephrolithiasis. Curr. Rheumatol. Rep. 9 (2007), 251–257.
116. [116] Terkeltaub, R.A., Clinical practice. Gout. N. Engl. J. Med. 349 (2003), 1647–1655.
117. [117] Rosival, V., Management of adult diabetic ketoacidosis. Diabetes Metab. Syndr. Obes. Targets Ther. 7 (2014), 255–264.
118. 2 transgene-control device. Mol. Cell 55 (2014), 397–408.
119. [119] Montague, M.G., Lartigue, C., Vashee, S., Synthetic genomics: potential and limitations. Curr. Opin. Biotechnol. 23 (2012), 659–665.
120. [120] Bugaj, L.J., Schaffer, D.V., Bringing next-generation therapeutics to the clinic through synthetic biology. Curr. Opin. Chem. Biol. 16 (2012), 355–361.
121. [121] Niu, Y., et al. Nanoparticles mimicking viral surface topography for enhanced cellular delivery. Adv. Mater. 25 (2013), 6233–6237.
122. [122] Hernández, R.M.A., Orive, G., Murua, A., Pedraz, J.L., Microcapsules and microcarriers for in situ cell delivery. Adv. Drug Deliv. Rev. 62 (2010), 711–730.
123. [123] Chang, T., Semipermeable microcapsules. Science 146 (1964), 524–525.
124. [124] Ausländer, S., Wieland, M., Fussenegger, M., Smart medication through combination of synthetic biology and cell microencapsulation. Metab. Eng. 14 (2012), 252–260.
125. [125] Orive, G., Santos, E., Pedraz, J.L., Hernández, R.M., Application of cell encapsulation for controlled delivery of biological therapeutics. Adv. Drug Deliv. Rev. 67–68 (2013), 3–14.
126. [126] Roberts, T., De Boni, U., Sefton, M.V., Dopamine secretion by PC12 cells microencapsulated in a hydroxyethyl methacrylate–methyl methacrylate copolymer. Biomaterials 17 (1996), 267–275.
127. [127] Garfinkel, M.S., Endy, D., Epstein, G.L., Friedman, R.M., Synthetic genomics | options for governance. Biosecur. Bioterror. 5 (2007), 359–362.
128. [128] Anderson, J.et al., Engineering and ethical perspectives in synthetic biology. Rigorous, robust and predictable designs, public engagement and a modern ethical framework are vital to the continued success of synthetic biology. EMBO Rep. 13 (2012), 584–590.
129. [129] Weber, W., Fussenegger, M., Synthetic gene networks in mammalian cells. Curr. Opin. Biotechnol. 21 (2010), 690–696.
130. [130] Ye, H., Aubel, D., Fussenegger, M., Synthetic mammalian gene circuits for biomedical applications. Curr. Opin. Chem. Biol. 17 (2013), 910–917.
131. [131] Rössger, K., Hamri, G.C., Fussenegger, M., A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nat. Commun. 4 (2013), 1–9.